NASDAQ$MNKD
MannKind Corp · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
MannKind reported revenue growth driven by Tyvaso DPI and progress in clinical development programs.
MannKind Corporation reported a 37% increase in total revenues for Q3 2024 compared to Q3 2023, reaching $70 million. The growth was primarily driven by increased royalties from Tyvaso DPI and higher collaboration and services revenue. The company also made significant progress in its clinical development programs, including the Phase 3 trial of MNKD-101 and the successful completion of the Phase 1 trial of MNKD-201.
- Total revenues for Q3 2024 reached $70 million, a 37% increase compared to Q3 2023.
- Royalties for Tyvaso DPI increased by 34% due to increased sales by United Therapeutics.
- Collaboration and services revenue increased by 78%, primarily due to increased manufacturing activities for Tyvaso DPI.
- Afrezza net revenue increased by 12% due to higher demand and improved gross-to-net adjustments.
Headline financials
Revenue & EPS history
MannKind · Revenue · Quarterly
$69.7M
Revenue by segment
MannKind · $31M total across 3 segments · Q3 2023
- Afrezza$13.5M—43.4%
- Collaborations and services$13.1M—42.2%
- V-Go$4.45M—14.3%
Forward guidance
MannKind anticipates several milestones in the near future, including data read-outs from clinical studies and regulatory submissions.
Tailwinds
- Primary endpoint analysis results from the Afrezza INHALE-1 Pediatric Phase 3 clinical trial are expected in 4Q 2024.
- Six-month data with safety extension from the Afrezza INHALE-1 Pediatric Phase 3 clinical trial are expected in 1H 2025.
- Additional data from the Afrezza INHALE-3 Phase 4 clinical trial will be presented at ATTD and other conferences in 1H 2025.
- Trial for MNKD-101 is cleared to proceed in four countries, with a fifth expected in 4Q 2024.
- FDA End-of-Phase 1 meeting for MNKD-201 is expected in 1H 2025.
Headwinds
- Risks associated with developing product candidates.
- Risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data.
- Risks associated with safety and other complications of our products and product candidates.
- Risks associated with the regulatory review process.
- Potential for actual results and the timing of events to differ materially from those anticipated in forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+1.5%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+44.9%
Q3 2016
Best reaction
-28.5%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.5% | +17.5% | +18.5% | |
| Q4 2025 | -6.9% | -16.3% | -34.9% | |
| Q3 2025 | +10.6% | -1.1% | +3.6% | |
| Q1 2025 | -4.5% | -2.7% | -9.7% | |
| Q4 2024 | -4.4% | -5.9% | -8.0% | |
| Q3 2024 | -1.2% | -4.8% | -8.6% | |
| Q2 2024 | -1.5% | -1.5% | +12.5% | |
| Q1 2024 | -3.6% | -1.3% | +4.5% | |
| Q4 2023 | +9.5% | +25.7% | +26.5% | |
| Q3 2023 | -0.8% | -6.8% | -0.3% | |
| Q2 2023 | +15.5% | +11.2% | -3.8% | |
| Q1 2023 | +13.4% | +9.0% | +6.2% | |
| Q4 2022 | +4.2% | +1.7% | -23.1% | |
| Q3 2022 | +6.3% | +20.7% | +32.8% | |
| Q2 2022 | -1.4% | -4.6% | -9.0% | |
| Q1 2022 | -8.7% | -8.7% | +42.7% | |
| Q4 2021 | -25.7% | -24.9% | -5.2% | |
| Q3 2021 | -0.6% | +3.1% | -14.3% | |
| Q2 2021 | +5.1% | +5.4% | +20.8% | |
| Q1 2021 | -8.4% | -3.9% | -8.0% | |
| Q4 2020 | -4.5% | -36.8% | -40.0% | |
| Q3 2020 | +8.8% | +19.0% | +43.9% | |
| Q2 2020 | +0.0% | -4.2% | -1.2% | |
| Q1 2020 | -2.2% | -0.7% | +4.5% | |
| Q4 2019 | -7.9% | -16.4% | -27.6% | |
| Q3 2019 | -15.1% | -16.8% | -18.8% | |
| Q2 2019 | -0.9% | +4.6% | +13.9% | |
| Q1 2019 | -12.3% | -19.4% | -25.2% | |
| Q4 2018 | +23.8% | +17.2% | +27.8% | |
| Q3 2018 | +0.0% | -1.1% | -2.7% | |
| Q2 2018 | -26.8% | -29.3% | -29.9% | |
| Q1 2018 | +2.3% | +8.7% | +13.3% | |
| Q4 2017 | -10.4% | -13.5% | -30.3% | |
| Q3 2017 | -7.1% | +0.3% | -4.3% | |
| Q2 2017 | -5.7% | -2.5% | +61.5% | |
| Q1 2017 | +13.8% | -5.4% | +39.3% | |
| Q4 2016 | +9.9% | +2.5% | -34.2% | |
| Q3 2016 | +44.9% | +51.2% | +51.2% | |
| Q2 2016 | -6.2% | +2.0% | -27.6% | |
| Q1 2016 | -28.5% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -19.9% | — | — | |
| Q2 2015 | +4.5% | — | — | |
| Q1 2015 | -8.4% | — | — | |
| Q4 2014 | +2.8% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -8.0% | — | — | |
| Q1 2014 | +5.8% | — | — | |
| Q4 2013 | +5.9% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q2 2013 | -5.1% | — | — | |
| Q1 2013 | +11.0% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | -8.3% | — | — | |
| Q4 2011 | +7.9% | — | — | |
| Q3 2011 | -1.6% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q1 2011 | -11.8% | — | — | |
| Q4 2010 | -5.5% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +3.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro